Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN-SA in Chronic Hepatitis C
NCT01903278Phase 3Completed
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Start
- Jun 2013
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfacon-2 in hepatitis C (HCV), sponsored by Beijing Kawin Technology Share-Holding Co., Ltd.. Started Jun 2013; status: completed.
02
Drugs
peginterferon alfacon-2
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01903278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01903278.